Purpose: The prevalence of epilepsy is increased in multiple sclerosis (MS), but information on AED treatment and seizure outcome is scarce. We describe epilepsy characteristics including the use of AEDs and proportion of seizure-free patients at two tertiary hospitals in Sweden. Method: We retrospectively studied electronic medical records of all patients with a diagnosis of MS and seizures at Sahlgrenska university hospital and Uppsala university hospital. Clinical data were reviewed until 2017. Results: We identified a total of 62 MS patients with at least one seizure. Median age at the first seizure (before or after MS) was 41 years (range 0-80). The most common MS disease course at the first seizure was secondary progressive MS, the neurological disability was considerable, and most patients had several MRI lesions at their first seizure. The first EEG demonstrated epileptiform discharges in 38% and unspecific pathology in 40%. Current seizure status could be determined for 37 patients. Out of these, 46% had been seizure free for more than one year at last follow-up. The majority of patients (65%) were on monotherapy at last follow-up. Carbamazepine was the most commonly used first AED, with a retention rate of 52%. No individual AED was associated with a particularly high rate of seizure freedom. The most common reason for discontinuation of the first AED was side-effects. Conclusion: Seizure freedom rates were low, perhaps indicating a need for higher ambitions in management. Side effects of AEDs may be a particular concern when treating epilepsy in patients with MS.
Introduction
The new ILAE classification of epilepsies emphasizes aetiology and comorbidities [1] . Epilepsy in several distinct patient groups previously studied together under the term "partial epilepsy" are now studied in an aetiology-stratified manner; examples include poststroke epilepsy [2] , autoimmune epilepsy [3] , or epilepsy after infectious encephalitis [4, 5] . In the era of person-centered care, such evidence is of great value for clinicians and health care providers trying to tailor therapy and management.
The prevalence of epilepsy is increased approximately threefold in multiple sclerosis (MS) [6, 7] . Seizures are more common in severe MS, which suggests a causal relationship between accumulated brain damage and epilepsy [8] . In contrast to the acquired epilepsies listed above, investigators have so far focused on describing the co-existence of MS and seizures, and as pointed out in thorough reviews, little information is available on optimal AED treatment and epilepsy outcome [9] . This most likely reflects the relative rarity of epilepsy in MS and the subsequent low number of subjects available for study at individual centers. One study identified ten cases of epilepsy among 310 MS patients, seven of whom had good seizure control (defined as "few seizures") [10] . Another study reported that seizure control was easily achieved in 22/36 patients (61.1%), but did not provide information on AED treatment [11] . An attempt at a Cochrane review showed no eligible studies [9, 12] . Recently, characteristics of epilepsy in MS was reported for 19 patients in a Norwegian single-center study, but the focus was not on epilepsy treatment and current seizure status [13] . In summary, there is shortage of systematic knowledge on management of epilepsy in MS. Given the increasing focus on aetiology in epilepsy, this is a considerable shortcoming À especially since worrying reports indicate that epilepsy in MS may have particular clinical characteristics; an unexpectedly high proportion of patients with status epilepticus and increased sensitivity to AED side effects [8, 12] .
We therefore performed a retrospective observational study on patients with seizures and MS at two of Sweden's larger tertiary neurology centers, with focus on seizure prognosis and AED response.
Methods

Cohort
The electronic patient registers at Sahlgrenska University Hospital, Gothenburg and Uppsala University Hospital, Sweden, contain information on all outpatient and inpatient contacts at each hospital. We searched the databases for all contacts with the neurology department during available years (Gothenburg 2000 -2013 , Uppsala 2007 -2016 and selected all patients with MS and at lest one code for seizure (R56.8) or epilepsy (G40.0-40.9). The search yielded 52 patients in Gothenburg and 15 patients in Uppsala. Among these, 47 patients in Gothenburg and 15 patients in Uppsala fulfilled the inclusion criteria (the records supporting at least one seizure and a diagnosis of MS). In five patients, the medical records revealed that the codes were erroneous, since either MS (n = 1) or seizures (n = 4) had not been present. These were excluded.
Review of records
Data were extracted from the medical records by use of a predefined clinical report form. EEG and MRI findings were categorized based on reports. Medical records were reviewed until April 2017 in Gothenburg and November 2017 in Uppsala and anonymized prior to analysis.
Statistics
Data are expressed as median and range for continuous variables and frequencies for categorical variables. Dates were approximated to the first day of the month or the year if the records did not contain exact information. If information was missing, the patient was omitted from that particular analysis. The exact number of patients in each analysis is given in tables or text. All analyses were performed using IBM SPSS version 23.
Ethical permission
The regional ethics committees of Gothenburg and Uppsala approved the study and waived the need for informed consent (Decisions Gothenburg 988-17 and Uppsala 397-17).
Results
Cohort and the first seizure
We identified 62 MS patients with seizures. Twenty-three patients were deceased. The median age at the first seizure was 41 years ( Table 1 ). The first seizure type was focal with impaired awareness or focal to bilateral tonic-clonic in most cases, but tonicclonic without clear focal onset in one third of cases ( Table 2 ). The year of the first seizure and the year of onset of MS symptoms could be determined for 60 patients. In 82% of cases, the first seizure was considered unprovoked and in 87% of cases the seizure occurred after the MS-diagnosis (Table 2 ). For one patient in Gothenburg, a seizure was the presenting symptom of MS. The median time from diagnosis of MS to the first seizure was ten years, and from the onset of MS symptoms eleven years (Fig. 1) . The most common disease stage at the time of the first seizure was secondary progressive MS, and the median expanded disability status scale (EDSS) score was 6.5 (0 = no disability, 10 = death in MS).
MRI and EEG findings
Twenty-nine patients had MRI results documented prior to their first seizure, with 93% demonstrating several lesions (semiquantitatively assessed from reports or images, refers to all lesions -not just juxtacortical). An MRI after the first seizure was available for 42 patients, 88% of which had more than five lesions (unfortunately, most MRI reports did not specify lesion distribution). EEG was available for 52 patients; 40% demonstrated unspecific pathology such as slowing, and 38% had epileptiform discharges. Forty-four patients with EEG results available had more seizures, including all twelve patients with normal EEGs. Among the six patients that did not have more than one seizure, three had epileptiform discharges and three had unspecific pathology.
AED choice
Out of all 62 patients, 54 had additional documented seizures. Sixteen patients had other possible reasons for an epilepsy diagnosis such as CNS tumor (n = 4), head trauma (n = 7), stroke (n = 2), or other (n = 3). We next characterized the treatment and treatment response to AEDs in patients with seizures and no other aetiology than MS (Table 3) . Information on the first AED could be found for 44 patients. The most commonly selected first drug was carbamazepine, followed by phenytoin, lamotrigine, and levetiracetam. Carbamazepine had been discontinued in almost half of the patients starting with this drug. For remaining AEDs, the numbers were small. The overall retention rate for the older AEDs carbamazepine, phenytoin, or valproic acid was 50% and that of newer AEDs lamotrigin, levetiracetam, gabapentin was 75% (p = 0.184, Fishers exact test).
Seizure outcome
At the time of last follow-up, seizure status could be determined for 37 patients (28 in Gothenburg and 9 in Uppsala). Among these, 50% had been seizure free for more than one year in Gothenburg and 33% in Uppsala. In total, 46% of patients were seizure free at last follow-up. Out of 20 patients being prescribed their first AED, 8 (40%) were seizure free. The majority of patients were on monotherapy, 10 patients were on a combination of AEDs and 3 patients were untreated. No single AED was associated with a particularly high proportion of seizure-free patients. We also analyzed the reason for discontinuation of the first AEDs, which was side effect of the AED in the majority of patients (Fig. 2) .
AAN quality parameters
We finally assessed AAN quality parameters in all patients with no alternative cause of epilepsy and outpatient follow-up information (n = 36). The year of last follow-up was 2015 (2000-2017, min-max). We focused only on seven out of eight AAN recommendations, as surgical referral was deemed not applicable to this patient population. Our data presents low rates of documentation for aetiology of epilepsy, as well as MRI and EEG review, and no patients were counseled regarding safety or reproductive health (Fig. 3) . Seizure type/frequency was documented at a higher rate (61%).
Discussion
Epilepsy in MS has mainly been studied as an outcome, most recently in a world-wide meta-analysis and in a large register-based population-wide study in Sweden [6, 14] . Epidemiological studies give excellent information on the prevalence and risk of epilepsy in MS, but are based on administrative data and cannot provide clinical detail. Such studies must therefore be supplemented by information Table 2 The first seizure. Semiology, MS characteristics and results of investigations. RRMS = relapsing remitting MS, SPMS = secondary progressive MS, PPMS = primary progressive MS. EDSS = Expanded disability status scale (0 = no disability, 10 = death in MS). [3] and postencephalitic epilepsy [4, 5] . Overall, our findings are well in line with the existing knowledge on epilepsy in MS. As in the epidemiological studies, the first seizure in our cohort occurred most often occurred some time after MS onset and a majority of patients were in secondary progressive MS at the time of their first seizure. Seizures very long before MS are probably unrelated to MS. The high proportion of focal seizure types is also in agreement with the literature [15] . The median EDSS score at the time of the first seizure was 6.5, indicating a high disability level.
These findings fit well with the notion that severity of MS is associated with risk of epilepsy. Our findings are also in agreement with those recently reported from a smaller cohort of 19 patients in a Norwegian single-center study [13] .
Most patients received carbamazepine as the first AED. The retention rate was higher for newer AEDs when used as the first drug compared to older AEDs, but the difference was not statistically significant and the shorter time in the market for newer drugs may have resulted in a shorter exposure time.
More than 60% of patients received carbamazepine or phenytoin as their first AED, and almost half the population were currently being treated with either compound at the time of the investigation. The widespread use of older sodium-channel blockers is interesting given the reports on increased side-effect sensitivity to such drugs in patients with MS [9, 16] . The enzyme-inducing properties of these drugs may also make them less suitable given other concomitant medication in severely affected MS patients, such as antidepressants. Treatment pattern and retention rates found in such a small patient material as ours is merely hypothesis-generating and we intend to investigate retention rates in a future nation-wide register-based investigation. Importantly, we report AED treatment for all patients with a seizure diagnosis and no other aetiology than MS that explains seizures. We cannot be certain that all seizures in the material were because of MS; seizures and or epilepsy can in rare cases occur by chance in patients with MS.
The most important finding of our study is the low rate of seizure freedom. Overall, two thirds of patients with epilepsy are expected to become seizure-free on AEDs, but only 44% of patients were seizure-free in our study population. This contrasts to some other reports, in which a majority of patients are described as having a benign seizure course [17] . The literature as a whole report very diverging results, but methodology such as follow-up time differs markedly [15] . Presumably, the introduction of electronic health records and raised therapeutic ambitions in both MS and epilepsy have improved data capture, giving contemporary reports an advantage over the older literature. We suggest at least three possible explanations for our finding of low rates of seizure freedom. The participating hospitals are tertiary centers, treating severely affected MS-patients in their respective regions. The low rate of seizure freedom could therefore reflect selection bias. Second, sensitivity to side effects may limit adequate dosing of AEDs and clinicians may not consider high doses justified in patients that are non-ambulatory and at low risk of seizure-related injuries. However, the doses used in our study population were not particularly low. Finally, it is possible that the low rates of seizure freedom reflect lower ambitions in management of seizures in patients with MS compared to the general epilepsy population. In poststroke epilepsy, another form of acquired epilepsy, the rate of seizure freedom at a Swedish tertiary center was considerably lower than those reported in clinical trials performed in the same patient group [18, 19] . In our study, low rates of seizure freedom were seen at both Swedish hospitals. One possible interpretation is that seizure freedom is not pursued as vigorously in the presence of another neurological disorder. Before independent replication in another country, this remains a concerning observation limited to Sweden. A low seizure freedom rate is of particular concern given the findings that patients with MS have repeatedly been shown to have an increased risk of status epilepticus [14, 20, 21] . Status epilepticus was not a predefined outcome measure in our investigation, but at least six patients (9.7%) in our cohort had status epilepticus (three EEG-verified in Gothenburg, and three clinically diagnosed in Uppsala). We also assessed the American Academy of Neurology (AAN) epilepsy quality measures [22] . The first four measures (seizure type/ frequency, aetiology, EEG, and neuroimaging) support the diagnostic approach and the last four measures (surgical referral, counseling about side effects, safety issues and reproductive health) supports quality of care. Our findings show limited documentation of quality parameters, indicating a need for raised ambitions in care of epilepsy in patients with MS, at least in Sweden.
In summary, we present the largest study of epilepsy and its treatment in patients with MS. Our findings validate recent register-based investigation and underline that epilepsy seems closely linked to MS severity. Like other investigators, we found that onset of epilepsy occurred mainly after MS. An interesting question is therefore if disease modifying therapy (DMT) of MS can prevent or mitigate epilepsy [15] . We did not address DMT in our material, since we only studied patients with seizures -but future studies are needed to elucidate if more aggressive management of MS can prevent epilepsy. From our current incomplete understanding of the pathophysiology of epilepsy in MS the relative contributions of inflammation and structural damage to epileptogenesis are not known, and may well differ in individual patients. We found low rates of seizure freedom in our material, with no indication of any particular AED being more effective than others. The retention rate for newer AEDs was higher than that of older AEDs, but not significantly so. This needs to be investigated further in larger patient materials -ideally large prospective trials.
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